S01E01: Your liver prefers chemotherapy over Ashwagandha

Is "natural" always safer? In this provocative episode, we dive into a surprising comparison of liver toxicity between the popular herbal supplement Ashwagandha and the chemotherapy combination Trifluridine/Tipiracil. While Ashwagandha is widely promoted for stress and sleep, the sources reveal a hidden side: documented cases of clinically apparent acute liver injury, jaundice, and hyperbilirubinemia linked to its use. Paradoxically, the chemotherapy drug Trifluridine/Tipiracil—despite its role in treating refractory cancer—is rated as an unlikely cause of liver injury (Likelihood Score E) and has not been implicated in the kind of severe jaundice seen in some Ashwagandha cases. Key highlights include:The "Natural" Fallacy: Why herbal supplements aren't always gentler on your organs than pharmaceutical drugs.Case Studies: A look at individuals who developed liver dysfunction after just one week to four months of Ashwagandha supplementation.Clinical Comparison: How a potent antineoplastic agent can actually have a lower risk of acute liver failure than a common "stress-relief" shrub.Safety Protocols: Essential warnings for patients with pre-existing liver conditions or thyroid disorders or those who are pregnant.Join us as we peel back the marketing to examine the hard clinical data on what your liver actually prefers.